Ranibizumab versus aflibercept for macular edema secondary to nonischemic central retinal vein occlusion in young adult patients

Résumé

Abstract Purposeto compare effect Ranibizumab and Aflibercept, for the treatment of macular edema secondary to non-ischemic central retinal vein occlusion CRVO in young adults.MethodsForty eyes of 40 young adult patients with macular edema due to CRVO were enrolled in this prospective double-armed clinical trial. The patients were randomized into 2 groups of 20 patients each. First group received intravitreal injection of Ranibizumab while second group received Aflibercept. All patients were subjected to measurement of Best corrected visual acuity BCVA, fluorescein angiography (FA) to detect retinal ischemia and Spectral domain OCT (SD-OCT) to measure macular edema at baseline and during 12-month follow up period. Intravitreal injections were three injections with a 1-month interval between injections.ResultsBCVA in group 1 had significant steady increase over time from baseline to 1 year [55.9 ± 10.3], p = 0.017). Group 2 had also significant steady increase over time from baseline to 1 year [60.8 ± 8.4], p = 0.035) with no significant difference between the 2 groups (p > 0.05). Regarding central subfield thickness CST, in the first group, statistically significant decrease in the CST over time from baseline to 1 year [295.1 ± 56 Um], p < 0.001). similar results in the second group from the baseline to 1 year [328.2 ± 72 Um] with no statistically significant difference (p > 0.05).ConclusionRanibizumab and aflibercept showed a comparable promising outcome in the management of macular edema secondary to nonischemic CRVO in patients aged < 50 years.Trial registration number : NCT05282420

Citer ce document

Accès au document

Ce document est hébergé sur son dépôt institutionnel d'origine.

Auteur(s)

Statistiques

Consultations : 1

Téléchargements : 0